MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./340/0.1/21.03.25 Stock

Warrant

DE000MG29F00

Real-time Bid/Ask 09:21:20 2024-05-23 EDT
0.135 EUR / 0.196 EUR +14.48% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./340/0.1/21.03.25
Current month-27.86%
1 month-25.64%
Date Price Change
24-05-23 0.135 -6.90%
24-05-22 0.145 +6.62%
24-05-21 0.136 +6.25%
24-05-20 0.128 -4.48%
24-05-17 0.134 -11.84%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 09:19 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG29F0
ISINDE000MG29F00
Date issued 2024-04-12
Strike 340 $
Maturity 2025-03-21 (302 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.22
Lowest since issue 0.116
Spread 0.072
Spread %35.29%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
234.4 USD
Average target price
279 USD
Spread / Average Target
+19.00%
Consensus